MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
- PMID: 32005272
- PMCID: PMC6995078
- DOI: 10.1186/s13045-020-0844-0
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Abstract
Background: PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib response, there are still evident limitations in the present approaches. Therefore, we aim to investigate more accurate approaches to predict Olaparib sensitivity and effective synergistic treatment strategies.
Methods: We probed two databases (TCGA and Qilu Hospital) in order to quest novel miRNAs associated with platinum-sensitivity or HR-related genes. Cellular experiments in vitro or in vivo and PDX models were utilized to validate their role in tumor suppression and Olaparib sensitizing. Furthermore, HR gene mutation was analyzed through WES to explore the relation between HR gene mutation and Olaparib response.
Results: High miR-509-3 expression indicated better response to platinum and longer progression-free and overall survival in two independent ovarian cancer patient cohorts (high vs. low miR-509-3 expression; PFS: TCGA P < 0.05, Qilu P < 0.05; OS: TCGA P < 0.05, Qilu P < 0.01). MiR-509-3 could impair the proliferation, migration, and invasion ability but enhance the sensitivity to Olaparib of ovarian cancer cell in vitro and in vivo by directly targeting HMGA2 and RAD51. In two PDX cases (PDX1 and PDX9), miR-509-3 could significantly increase the sensitivity to Olaparib along with the decrease of RAD51 positive rate (mean tumor weight NC + Olaparib vs. miR-509 + Olaparib; PDX1 P < 0.05, PDX9 P < 0.05). Additionally, in PDX8, miR-509-3 treatment dramatically reversed the Olaparib insensitivity (P < 0.05) by downregulating RAD51 expression. RAD51 functional detection revealed that all Olaparib sensitive cases exhibited low RAD51 positive rate (lesser than 50%) in treated groups. Furthermore, among the four HR gene mutation patients, three harbored HR core gene mutation and were sensitive to Olaparib while the remaining one with non-HR core gene mutation did not respond well to Olaparib.
Conclusions: MiR-509-3 can sensitize ovarian cancer cells to Olaparib by impeding HR, which makes it a potential target in PARPi synergistic treatment. HR core gene analysis and RAD51 functional detection are prospectively feasible in prediction of PARPi response.
Keywords: PARPi; PDX; RAD51; Synthetic lethality; miR-509-3.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6995078/bin/13045_2020_844_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6995078/bin/13045_2020_844_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6995078/bin/13045_2020_844_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6995078/bin/13045_2020_844_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6995078/bin/13045_2020_844_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6995078/bin/13045_2020_844_Fig6_HTML.gif)
Similar articles
-
The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.Gynecol Oncol. 2020 Dec;159(3):850-859. doi: 10.1016/j.ygyno.2020.09.018. Epub 2020 Sep 23. Gynecol Oncol. 2020. PMID: 32980128
-
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11. Gynecol Oncol. 2014. PMID: 24631446 Free PMC article.
-
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.Gynecol Oncol. 2020 Dec;159(3):869-876. doi: 10.1016/j.ygyno.2020.09.040. Epub 2020 Oct 5. Gynecol Oncol. 2020. PMID: 33032822 Free PMC article.
-
[Abnormalities of DNA repair and gynecological cancers].Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18. Bull Cancer. 2017. PMID: 29054544 Review. French.
-
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16. Expert Opin Investig Drugs. 2016. PMID: 26899229 Review.
Cited by
-
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.J Exp Clin Cancer Res. 2024 May 15;43(1):146. doi: 10.1186/s13046-024-03065-0. J Exp Clin Cancer Res. 2024. PMID: 38750579 Free PMC article. Review.
-
The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.Cancer Med. 2023 Dec;12(24):22370-22380. doi: 10.1002/cam4.6725. Epub 2023 Nov 20. Cancer Med. 2023. PMID: 37986697 Free PMC article.
-
Study of MicroRNA Cluster Located on Chromosome X in Serum and Breast Cancer Tissue.Biochem Genet. 2024 Apr;62(2):1115-1135. doi: 10.1007/s10528-023-10448-z. Epub 2023 Aug 6. Biochem Genet. 2024. PMID: 37544000
-
Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes.Int J Gynecol Cancer. 2023 Sep 4;33(9):1427-1433. doi: 10.1136/ijgc-2023-004483. Int J Gynecol Cancer. 2023. PMID: 37541687 Free PMC article.
-
Comprehensive analysis of m6A-modified circRNAs in peritoneal metastasis of high grade serious carcinoma of ovary.Front Oncol. 2022 Sep 20;12:988578. doi: 10.3389/fonc.2022.988578. eCollection 2022. Front Oncol. 2022. PMID: 36203450 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials